ICER publishes final findings on bluebird bio's beti-cel

Unofficial American cost-effectiveness watchdog the Institute for Clinical and Economic Review (ICER) has published a Final Evidence Report on betibeglogene autotemcel for the treatment of beta thalassemia.

Often abbreviated as beti-cel, this gene therapy from bluebird bio (Nasdaq: BLUE) is set to be sold under the brand name Zynteglo, should it gain approval from the US Food and Drug Administration (FDA).

"Beti-cel is cost-effective at a high price in part because it offsets current very high costs of care"David Rind, the ICER’s chief medical officer, explained the prognosis that patients with beta thalassemia, a serious blood disorder, are currently faced with.